Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.
about
Role and New Insights of Pirfenidone in Fibrotic DiseasesPhototoxicity: Its Mechanism and Animal Alternative Test MethodsNewer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis.Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling
P2860
Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@ast
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@en
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@nl
type
label
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@ast
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@en
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@nl
prefLabel
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@ast
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@en
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@nl
P2093
P2860
P1476
Inhalable powder formulation o ...... eatment of pulmonary fibrosis.
@en
P2093
Masashi Kato
Satomi Onoue
Shizuo Yamada
Yoshiki Kojo
Yoshiki Seto
Yosuke Aoki
P2860
P304
P356
10.1007/S11095-013-0997-4
P577
2013-02-21T00:00:00Z